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Summary
BACKGROUND: Neonatal screening and treatment of
phenylketonuria (PKU) prevent the development of neuro-
cognitive impairment. The degree of dysfunction may be
related to metabolic control and responsible for a hampered
school career.
METHODS: This was a retrospective study from a single
metabolic unit of a Swiss University Hospital. The time
point of diagnosis and all Phenylalanin (Phe) concentra-
tions during the follow-up were recorded. The primary
outcome was integration into professional life defined as
no professional studies versus accomplished apprenticeship
versus high school diploma/university. Phe levels were cor-
related with professional outcome. The control group con-
sisted of the patients’ healthy parents and siblings.
RESULTS: A total of 27 patients (13 females, 14 males)
were included in the study. The mean (SD) follow-up peri-
od was 25.1 (7.6) years. The control group consisted of 57
subjects. Overall, 23 patients were diagnosed by neonatal
screening, and 4 patients were diagnosed later. All 4 were
in the non-professional study group. Compared with the
controls there were significantly more patients in the non-
professional study group (26% vs 9%, p <0.05) and sig-
nificantly less in the accomplished apprenticeship group
(59% vs 82%; p <0.04). After exclusion of the patients with
late diagnosis no significant differences were found with
regard to the professional integration between patients and
controls. Significant differences in Phe-levels between the
three groups could be documented between 2–10 years of
age with the highest levels in the non-professional study
followed by the accomplished apprenticeship and the high
school diploma group (p <0.01).
CONCLUSION: Patients who are diagnosed by neonatal
screening and are consequently cared for are able to accom-
plish an apprenticeship or a high school diploma.
Reference to electronic database: Phenylketonuria MIM
# 261600
Key words: Phenylketonuria; professional integration;
long-term follow-up
Introduction
Phenylketonuria (PKU) is an autosomal-recessive inherited
metabolic disease, due to partial or complete phenylalanine
hydroxylase deficiency (PAH), the enzyme responsible for
the conversion of phenylalanine to tyrosine [1]. Its incid-
ence is 1:8000 births in Switzerland, PKU and hyperph-
enylalaninaemia included [2]. PAH deficiency leads to
neurotoxic phenylalanine (Phe) accumulation, causing ir-
reversible damage to the developing central nervous sys-
tem (CNS) [3]. Nowadays, owing to newborn screening,
the disease can be diagnosed within a few days after birth
and therapy can be initiated.
At birth, the children are completely healthy. However,
if nutritional therapy is not implemented as soon as pos-
sible, severe mental retardation may ensue [4]. In addition,
eczema and the typical “musty and mousy” smell of skin,
hair, sweat and urine can result [3]. Amongst these symp-
toms particularly the impaired CNS function and the asso-
ciated difficulties of the school career have a high impact
on the integration into the professional life of these pa-
tients.
Long-term outcome data – including childhood and adult-
hood – in patients with PKU in relation to metabolic con-
trol are scarce. They have mainly focused on neuropsy-
chological parameters such as Intelligence quotient (IQ) or
executive functions [5]. There is data indicating that ad-
equate control of blood phenylalanine levels is effective in
preventing most of the CNS deficits [6]. However, even
in treated patients with PKU subtle disabilities remain in-
cluding lower average IQ [5, 7] and impaired executive
function of CNS [8]. Importantly, the degree of impairment
appears to be correlated with life time exposure to Phe con-
centrations, in particular the exposure during early child-
hood [9]. Low IQ and impaired executive CNS function
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impact on school career and integration into professional
life.
Accordingly, we aimed to investigate the long-term follow-
up of patients with PKU in relation to Phe exposure during
childhood and adulthood. We hypothesised that the time
point of diagnosis and the Phe exposure during follow-up
has a significant impact on the integration into the profes-
sional life.
Methods
In this retrospective analysis all adult patients with PKU
currently treated at the adult Divison of Endocrinology,
Diabetology and Clinical Nutrition of the Inselspital, Bern,
Switzerland were included. During childhood, they were
treated by the paediatric metabolic team, which collabor-
ates with the adult metabolic team where the patients are
transferred, usually at the age of 16–18 years. Importantly,
only patients that needed a dietary intervention during the
follow-up were included. The data recorded were the time
Figure 1
Age dependent Phenylalanine concentrations (mean ± SD). With
advancing age, mean Phe-concentrations of the whole cohort
increase.
Figure 2
Professional integration in relation to Phenylalanine concentrations
during the whole follow-up period.
In all three age groups, the patients of the non-professional study-
group have the highest and the patients of the high school diploma-
group the lowest mean Phenylalanine concentrations. The
accomplished apprenticeship-group present with Phe
concentrations in-between. Statistical significant differences were
detected in the age-group of 2–10 years.
There was a tendency for higher values with advancing age, in
particular in the apprenticeship group.
1 = high school diploma or university; 2 = accomplished
apprenticeship at least 3 years; 3 = no professional studies/
disability annuity.
* Target range in the respective age group according to the
recommendation of the Swiss Metabolic Group [10]
point of the diagnosis (by neonatal screening vs. diagnosis
in childhood), all phenylalanine-concentrations measured
during the follow-up (expressed as mean phenylalanine
level/year and patient), the professional career, the addi-
tional specialised schooling support and potential difficult
psychosocial context.
The primary outcome was documented as patients with a
high school or university diploma (high school diploma),
patients who accomplished an apprenticeship (accom-
plished apprenticeship) and patients with an inability to
complete professional studies and/or with disability annu-
ity in adulthood (non-professional study). The secondary
outcomes were (1.) specialised schooling support defined
as speech therapy, ergotherapy, dyslexia training and spe-
cial school classes and (2.) psychosocial difficulties
defined as financial problems and/or psychological therapy
and/or broken home. Both had to be documented in the
files.
Symptoms of the central nervous system included docu-
mented mental retardation and/or speech disorders, and/
or neurocognitive impairment and/or attention deficit syn-
drome.
The frequency of Phe-concentrations measurements were
highest in neonates and young children (once monthly up
to one measurement every three months) and much lower
in adulthood (1–2 times/year). The frequency of Phe-as-
sessment mainly depended on the quality of metabolic con-
trol and was, therefore, not standardised. We, therefore, es-
timated life time Phe exposure as follows: every measured
Phe-concentration in all patients was recorded. A mean
Phe-concentration/year/patient was calculated. All the Phe
concentrations of the patients were depicted in relation to
their age (fig. 1). In addition, the mean of all recorded
Phe concentrations of the age group (0–2, 2–10, >10 years)
per patient was calculated and depicted in relation to the
primary outcome (integration into the professional life; i.e.
non-professional study; accomplished apprenticeship, high
school diploma) and age group (fig. 2). The different time
period of observation was chosen according to the thera-
peutic guidelines of the Swiss Metabolic Group for the
follow-up of patients with phenylketonuria (0–2 years,
2–10 years and >10 years, [10]).
The control group consisted of all the healthy siblings and
parents of the patients.
The study protocol was submitted to the ethics committee
and based on the authorisation for retrospective research
(Klinikbewilligung 30 June 2003 between the Inselspital
and the Bundesamt für Gesundheit) was approved by the
director of research (KEKBE 07–02–2011).
Statistics
All parameters are given as mean ± SD. Phe-concentrations
between the outcome groups (non-professional study, ac-
complished apprenticeship and high school diploma) were
compared using two-way ANOVA. The comparisons
between the patients group and the control group was per-
formed by Fisher’s exact test. All analysis were carried out
using the statistic program Instat (La Jolla, CA, USA).
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Results
Clinical characteristics (table 1 and 2) of the patients
and the control subjects
The main clinical characteristics are summarised in table 1.
A total of 27 patients (13 females, 14 males) were included
in the study. The mean (SD) age at the last visit was 27.4
(7.9) years. The range was between 18 and 45 years. The
mean follow-up period was 25.1 (7.6) years (range 17–43
years).
A total of 23 patients were diagnosed by neonatal screen-
ing, and the 4 remaining patients were diagnosed later dur-
ing early childhood.
The patients were controlled at least once a month during
their childhood (until the age of 5–7 years) and once or
twice a year during puberty and adulthood.
A total of 57 controls subjects were recruited. This group
consisted of the healthy siblings and parents of the patients,
including 26 (45.6%) female and 31 male subjects (54.4%).
Integration into the professional life of patients and
controls (table 2 and 3)
Seven patients (26%) did not accomplish professional stud-
ies and six of them (22%) required disability annuity (non-
professional study). A total of 16 patients (59%) accom-
plished an apprenticeship (accomplished apprenticeship)
and 4 patients (15%) went to a high school or graduated at
university (high school diploma). All patients in the accom-
plished apprenticeship and high school diploma group were
diagnosed by neonatal screening meanwhile 4 patients (out
of seven) from the non-professional study group were dia-
gnosed during early childhood (18 months up to 3 years
old). There were no significant differences with regard to
patients with mild PKU versus classical PKU in the three
outcome groups.
The control group consisted of 57 subjects (healthy parents
and siblings). A total of 9% (5 persons) were in the non-
professional study-group, significantly less than in the pa-
tient group (p <0.05), 82% (47 persons) were in the ac-
complished apprenticeship-group, significantly more than
in the patient group (p <0.04), and 9% (5 persons) were in
the high school diploma-group with no statistical differen-
ce compared to the patients.
By excluding the four patients that were not diagnosed
by neonatal screening there were no significant differences
with regard to the integration into professional life between
the patients and the controls.
Specialised schooling support (table 2)
A total of 55% of all patients needed specialised schooling
support during childhood. In the non-professional study
group, all 7 patients (100%) had specialised schooling sup-
port whereas in the accomplished apprenticeship group
only 7 of 16 (44%) benefitted from this support. In the high
school diploma group only one patient of four (25%) re-
quired it (table 2).
Metabolic control (fig. 1 and 2)
The mean age-dependent phenylalanine-concentrations are
depicted in figure 1. There was a tendency for increasing
Phenylalanine concentrations with increasing age. This is
mainly due to a less strict control of Phe concentrations in
the accomplished apprenticeship group.
In figure 2 the mean Phenylalanine concentrations in rela-
tion to the primary professional outcome (non-professional
study, accomplished apprenticeship, high school diploma)
are depicted.
The mean (SD) Phe levels of the non-professional study-
group were: 0–2 years: 578 (307) μmol/l; 2–10 years: 679
(287) μmol/l; >10 years: 747 (310) μmol/l. The mean levels
in this group were all above the recommended Phe target of
the corresponding age group.
The mean (SD) Phe levels of the accomplished
apprenticeship-group were: 0–2 years: 456 (156) μmol/l;
2–10 years: 454 (125) μmol/l; >10 years: 712 (284) μmol/l.
The mean levels in this group were at the upper limit of the
corresponding age and increased with advancing age.
The mean (SD) Phe levels of the high school diploma-
group were: 0–2 years: 360 (62) μmol/l; 2–10 years: 320
(62) μmol/l; >10 years: 379 (98) μmol/l. The mean values
were in the target range throughout the follow-up.
In the age period 0–2 years there was no statistical signific-
ant difference between the three outcome groups. This was
due to the lack of sufficient data in this age group, related
to the late diagnosis of 4 patients in the non-professional
study group. Significant differences in Phe levels between
the accomplished apprenticeship and the non-profession-
al study group and the high diploma and the non-profes-
sional study group can be documented between 2–10 years
with highest levels in the non-professional study group,
followed by the accomplished apprenticeship and the high
school diploma group (ANOVA p <0.01). In the oldest age
group (>10 years old), there was only a tendency for signi-
ficant differences using the ANOVA model (p = 0.09). The
increase in the Phe levels in the accomplished apprentice-
ship group accounted for this result.
Non-professional study/disability annuity group (table
3)
Seven patients (27%) did not accomplish professional stud-
ies. Potential causes for this outcome are summarised in
table 3. The main reasons were late diagnosis of PKU
mainly associated with CNS dysfunction (4 out of seven
patients). The remaining 3 patients experienced a difficult
psychosocial context and/or did not adhere to the therapy.
Discussion
To our knowledge this is the first study specifically in-
vestigating the professional outcome of patients with PKU
from childhood until adulthood in a single Swiss tertiary
referral centre in relation to the metabolic control during
the follow-up. The main findings can be summarised as fol-
lows. (1.) The time of diagnosis and the psychosocial con-
text are essential for patients’ professional careers. (2.) The
professional outcome of patients with PKU that are dia-
gnosed by neonatal screening is not significantly different
compared with a control population (3.) The exposure to el-
evated Phe levels during childhood may interfere with the
professional success of the patients. (4.) Additional special-
ised schooling support is necessary for a substantial num-
ber of patients.
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The mean phenylalanine-concentrations of the whole co-
hort increased with increasing age of the patients (fig. 1)
consistent with data from other cohorts [11] and reflects the
less strict control from childhood to adulthood. This is con-
sistent with the target Phe concentrations with increasing
age [10].
Patients with PKU accomplished professional studies (ap-
prenticeship) significantly less often and received disability
annuity significantly more often compared to controls.
However, a similar percentage of patients passed a high
school diploma compared with the controls. Interestingly,
throughout the whole follow-up Phe exposure was signific-
antly higher than the recommended target concentrations in
the group without professional studies whereas in the ac-
complished apprenticeship group Phe levels during child-
hood were at the upper acceptable limit and increased with
increasing age (fig. 2). In contrast, patients with a high
school diploma had Phe levels mainly within the target
range throughout the whole follow-up (fig. 2). If we as-
sume that IQ, CNS executive function and psychological
behaviour affect the integration into professional life and
are related to metabolic control, the present data are con-
sistent with the available information in the literature [12,
13]. It also indicates that a lifetime Phe exposure within the
recommended target is compatible with high school dip-
loma and studies at the university.
Seven patients (26%) did not accomplish professional stud-
ies and six of them (22%) received disability annuity (table
3). In comparison, in 2012 only about 5% of the Swiss
population received disability annuity [14]. Four patients
in this group were not diagnosed by neonatal screening
but during early childhood. The age of definite diagnosis
ranged from 18 months until 3 years old. These patients
had immigrated to Switzerland from a country where
neonatal screening was not mandatory or not available.
These patients presented with symptoms and signs of CNS
dysfunction that influenced their respective school career.
Excluding the four patients with late diagnosis, the patients
with PKU had a similar integration into professional life
Table 1: Integration into professional life of the patients and the control group.
No professional studies Accomplished apprenticeship High school diploma
Patients (all) 7 (26%)c 16 (59%)b 4 (15%)NS
Patients (excluding patients with late
diagnosis)
3 (13%) NS 16 (70%) NS 4 (17%) NS
Gender 3F/4M 7F/9M 2F/2M
Time point of diagnosis Late diagnosis:
57% (4)
Screening:
100% (16)
Screening:
100% (4)
Specialised schooling supporta 7 (100%) 7 (44%) 1 (25%)
Control group Parents:
Siblings:
5 (9%)
4 (10.5%)
1 (5.5%)
47 (82%)
32 (84%)
15 (79%)
5 (9%)
2 (5.5%)
3 (15.5%)
a Defined as logopaedia, ergotherapy, legasthenia training, special school classes; b = p <0.04; c = p <0.05.
NS = no statistical difference.
Table 2: Clinical characteristics of patients with no professional studies/disability annuity.
Patient no. LD DA CNS-symptomsa Difficult psychosocial
contextb
1 – + – +
2 + + + –
3 + – + –
4 – + – +
5 + + + +
6 + + + –
7 – + + +
LD = Late diagnosis; DA = disability annuity.
a CNS-symptoms = central nervous system, defined as mental retardation, speech disorder, neurocognitive impairment, attention deficit
syndrome.
b Difficult psychosocial context: defined as financial problems and/or broken home and/or need for psychiatric therapy.
Table 3: Clinical Characteristics of Patients with no Professional Studies/Disability Annuity.
No of patient Late diagnosis DA# Symptoms of the CNS§ Malcompliance Difficult psychosocial
context
1 – + + +
2 + + + +
3 + – +
4 – + + +
5 + + + +
6 + + +
7 – + + + +
§ Symptoms of the CNS = central nervous system, defined as mental retardation, speech’s disorder, neurocognitive impairment, attention deficit
syndrome. # DA = disability annuity
Difficult psychosocial context: defined as financial problems and/or broken home and/or need for psychiatric therapy.
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compared with the control group further substantiating the
importance of early diagnosis of PKU.
More than half of the patients needed specialised schooling
support, decreasing in frequency from the non-professional
study to the accomplished apprenticeship and the high
school diploma group, in keeping with data from the Neth-
erlands [15] and Germany [16]. It is conceivable that these
data can be considered as an early hint in childhood for a
later difficult task for the professional integration of these
patients. It also supports the notion that the main diffi-
culties of these patients are related to the school career
and that sustained support is necessary in order to integrate
these patients later into professional life.
This study has limitations: (1.) It is a retrospective analysis.
We deliberately included a reliable primary endpoint such
as the integration into professional life. We did not include
measurements of quality of life that are influenced by a
panoply of confounding factors that may change over time.
(2.) We included all patients with increased Phe levels
(>600 μmol/l) in early childhood or at neonatal screening
that needed regular follow-up and nutritional therapy. We
are aware that patients with mild PKU have a lower risk
for neuropsychological dysfunction that may affect the in-
tegration into professional life. However, the percentage of
patients with mild PKU versus classical PKU was similar
in the three groups and there are data suggesting that pa-
tients with hyperphenylalaninaemia can also present with
decreased CNS executive functioning [17]. (3.) Based on
the small sample size of the subgroups we were not able to
clearly distinguish between the negative effect of late dia-
gnosis and Phe exposure during childhood.
In conclusion, these findings indicate that patients with
PKU who are diagnosed at neonatal screening and are con-
sequently cared for during childhood and adulthood can ac-
complish an apprenticeship or a high school diploma. In
contrast, late diagnosis and a difficult psychosocial context
remains a significant risk for a poor school career. Import-
antly, specialised schooling support is important in more
than 50% of these patients.
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Figures (large format)
Figure 1
Age dependent Phenylalanine concentrations (mean ± SD). With advancing age, mean Phe-concentrations of the whole cohort increase.
Figure 2
Professional integration in relation to Phenylalanine concentrations during the whole follow-up period.
In all three age groups, the patients of the non-professional study-group have the highest and the patients of the high school diploma-group the
lowest mean Phenylalanine concentrations. The accomplished apprenticeship-group present with Phe concentrations in-between. Statistical
significant differences were detected in the age-group of 2–10 years.
There was a tendency for higher values with advancing age, in particular in the apprenticeship group.
1 = high school diploma or university; 2 = accomplished apprenticeship at least 3 years; 3 = no professional studies/disability annuity.
* Target range in the respective age group according to the recommendation of the Swiss Metabolic Group [10].
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